The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors

Adenosine modulates immune/inflammatory reactions. This study investigates the expression of adenosine deaminase in the inflamed colon, the effects of adenosine deaminase inhibitors on established colitis, and the recruitment of adenosine receptors by endogenous adenosine after adenosine deaminase b...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of pharmacology and experimental therapeutics 2010-11, Vol.335 (2), p.434-442
Hauptverfasser: Antonioli, Luca, Fornai, Matteo, Colucci, Rocchina, Awwad, Oriana, Ghisu, Narcisa, Tuccori, Marco, Da Settimo, Federico, La Motta, Concettina, Natale, Gianfranco, Duranti, Emiliano, Virdis, Agostino, Blandizzi, Corrado
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 442
container_issue 2
container_start_page 434
container_title The Journal of pharmacology and experimental therapeutics
container_volume 335
creator Antonioli, Luca
Fornai, Matteo
Colucci, Rocchina
Awwad, Oriana
Ghisu, Narcisa
Tuccori, Marco
Da Settimo, Federico
La Motta, Concettina
Natale, Gianfranco
Duranti, Emiliano
Virdis, Agostino
Blandizzi, Corrado
description Adenosine modulates immune/inflammatory reactions. This study investigates the expression of adenosine deaminase in the inflamed colon, the effects of adenosine deaminase inhibitors on established colitis, and the recruitment of adenosine receptors by endogenous adenosine after adenosine deaminase blockade. Adenosine deaminase expression was determined by Western blot. The effects of 4-amino-2-(2-hydroxy-1-decyl)pyrazole[3,4-d]pyrimidine (APP; a novel adenosine deaminase inhibitor), erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA; a reference adenosine deaminase inhibitor), dexamethasone, and selective adenosine receptor antagonists were tested in rats with 2,4-dinitrobenzenesulfonic acid-induced colitis. Systemic (food intake, body and spleen weight) and colonic [macroscopic/microscopic damage, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and malondialdehyde (MDA)] inflammatory parameters were assessed. Test drugs were administered intraperitoneally for 6 days, starting at day 5 from colitis induction. Adenosine deaminase was detected in normal colon, and its expression was increased in inflamed tissues. Colitis was associated with decreased food intake and body weight, augmented spleen weight, and increased levels of colonic TNF-α, IL-6, and MDA. APP or EHNA, but not dexamethasone, improved food intake and body weight. APP, EHNA, and dexamethasone counteracted the increments of spleen weight, ameliorated macroscopic and microscopic indexes of inflammation, and reduced TNF-α, IL-6, and MDA levels. The beneficial effects of APP and EHNA on inflammatory parameters were prevented by the pharmacological blockade of A(2A) or A(3) receptors, but not A(1) or A(2B). The present results show that: 1) bowel inflammation is associated with an enhanced adenosine deaminase expression; and 2) the anti-inflammatory actions of adenosine deaminase inhibitors against chronic established colitis depend on the sparing of endogenous adenosine, leading to enhanced A(2A) and A(3) receptor activation.
doi_str_mv 10.1124/jpet.110.171223
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_759521994</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>759521994</sourcerecordid><originalsourceid>FETCH-LOGICAL-p125t-af6b1a60f1d8c4289b1c2527802f4c811eca22efa5ff17cc4a2f8118d84e00d3</originalsourceid><addsrcrecordid>eNpVkDtPwzAUhS0kREthZkPemAK247zGqIKCVImle3TjXFOXJA62I8Ef4HfjijIwnfv4dKRzCLnh7J5zIR8OE4Y4xa3gQqRnZMkzwRPGWbogl94fGONS5ukFWQiW5yXL0iX53u2Rtr1V79AhtZpGGa03I9IOYTAjeKQwYG-sg4Ceqr2zo1EUPyd0ZsAxQE-V7U0wnob4nN_2UZE6VG424Uj8961FTWHsaJ0eGZyCdf6KnGvoPV6fdEV2T4-79XOyfd28rOttMnGRhQR03nLImeZdqaQoq5YrkYmiZEJLVXKOCoRADZnWvFBKgtDxWnalRMa6dEXufm0nZz9m9KEZjFfY9zCinX1TZFWsrKpkJG9P5NwO2DVTzAruq_lrLv0BoQxxQA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>759521994</pqid></control><display><type>article</type><title>The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Antonioli, Luca ; Fornai, Matteo ; Colucci, Rocchina ; Awwad, Oriana ; Ghisu, Narcisa ; Tuccori, Marco ; Da Settimo, Federico ; La Motta, Concettina ; Natale, Gianfranco ; Duranti, Emiliano ; Virdis, Agostino ; Blandizzi, Corrado</creator><creatorcontrib>Antonioli, Luca ; Fornai, Matteo ; Colucci, Rocchina ; Awwad, Oriana ; Ghisu, Narcisa ; Tuccori, Marco ; Da Settimo, Federico ; La Motta, Concettina ; Natale, Gianfranco ; Duranti, Emiliano ; Virdis, Agostino ; Blandizzi, Corrado</creatorcontrib><description>Adenosine modulates immune/inflammatory reactions. This study investigates the expression of adenosine deaminase in the inflamed colon, the effects of adenosine deaminase inhibitors on established colitis, and the recruitment of adenosine receptors by endogenous adenosine after adenosine deaminase blockade. Adenosine deaminase expression was determined by Western blot. The effects of 4-amino-2-(2-hydroxy-1-decyl)pyrazole[3,4-d]pyrimidine (APP; a novel adenosine deaminase inhibitor), erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA; a reference adenosine deaminase inhibitor), dexamethasone, and selective adenosine receptor antagonists were tested in rats with 2,4-dinitrobenzenesulfonic acid-induced colitis. Systemic (food intake, body and spleen weight) and colonic [macroscopic/microscopic damage, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and malondialdehyde (MDA)] inflammatory parameters were assessed. Test drugs were administered intraperitoneally for 6 days, starting at day 5 from colitis induction. Adenosine deaminase was detected in normal colon, and its expression was increased in inflamed tissues. Colitis was associated with decreased food intake and body weight, augmented spleen weight, and increased levels of colonic TNF-α, IL-6, and MDA. APP or EHNA, but not dexamethasone, improved food intake and body weight. APP, EHNA, and dexamethasone counteracted the increments of spleen weight, ameliorated macroscopic and microscopic indexes of inflammation, and reduced TNF-α, IL-6, and MDA levels. The beneficial effects of APP and EHNA on inflammatory parameters were prevented by the pharmacological blockade of A(2A) or A(3) receptors, but not A(1) or A(2B). The present results show that: 1) bowel inflammation is associated with an enhanced adenosine deaminase expression; and 2) the anti-inflammatory actions of adenosine deaminase inhibitors against chronic established colitis depend on the sparing of endogenous adenosine, leading to enhanced A(2A) and A(3) receptor activation.</description><identifier>EISSN: 1521-0103</identifier><identifier>DOI: 10.1124/jpet.110.171223</identifier><identifier>PMID: 20668053</identifier><language>eng</language><publisher>United States</publisher><subject>Adenine - analogs &amp; derivatives ; Adenine - pharmacology ; Adenine - therapeutic use ; Adenosine Deaminase - biosynthesis ; Adenosine Deaminase Inhibitors ; Animals ; Blotting, Western ; Body Weight - drug effects ; Chronic Disease ; Colitis - enzymology ; Colitis - immunology ; Colitis - metabolism ; Colitis - prevention &amp; control ; Colon - drug effects ; Colon - enzymology ; Colon - immunology ; Colon - metabolism ; Cytokines - immunology ; Disease Models, Animal ; Enzyme Inhibitors - pharmacology ; Enzyme Inhibitors - therapeutic use ; Male ; Organ Size - drug effects ; Pyrazoles - pharmacology ; Pyrazoles - therapeutic use ; Pyrimidines - pharmacology ; Pyrimidines - therapeutic use ; Rats ; Rats, Sprague-Dawley ; Receptor, Adenosine A2A - metabolism ; Receptor, Adenosine A3 - metabolism</subject><ispartof>The Journal of pharmacology and experimental therapeutics, 2010-11, Vol.335 (2), p.434-442</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20668053$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Antonioli, Luca</creatorcontrib><creatorcontrib>Fornai, Matteo</creatorcontrib><creatorcontrib>Colucci, Rocchina</creatorcontrib><creatorcontrib>Awwad, Oriana</creatorcontrib><creatorcontrib>Ghisu, Narcisa</creatorcontrib><creatorcontrib>Tuccori, Marco</creatorcontrib><creatorcontrib>Da Settimo, Federico</creatorcontrib><creatorcontrib>La Motta, Concettina</creatorcontrib><creatorcontrib>Natale, Gianfranco</creatorcontrib><creatorcontrib>Duranti, Emiliano</creatorcontrib><creatorcontrib>Virdis, Agostino</creatorcontrib><creatorcontrib>Blandizzi, Corrado</creatorcontrib><title>The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors</title><title>The Journal of pharmacology and experimental therapeutics</title><addtitle>J Pharmacol Exp Ther</addtitle><description>Adenosine modulates immune/inflammatory reactions. This study investigates the expression of adenosine deaminase in the inflamed colon, the effects of adenosine deaminase inhibitors on established colitis, and the recruitment of adenosine receptors by endogenous adenosine after adenosine deaminase blockade. Adenosine deaminase expression was determined by Western blot. The effects of 4-amino-2-(2-hydroxy-1-decyl)pyrazole[3,4-d]pyrimidine (APP; a novel adenosine deaminase inhibitor), erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA; a reference adenosine deaminase inhibitor), dexamethasone, and selective adenosine receptor antagonists were tested in rats with 2,4-dinitrobenzenesulfonic acid-induced colitis. Systemic (food intake, body and spleen weight) and colonic [macroscopic/microscopic damage, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and malondialdehyde (MDA)] inflammatory parameters were assessed. Test drugs were administered intraperitoneally for 6 days, starting at day 5 from colitis induction. Adenosine deaminase was detected in normal colon, and its expression was increased in inflamed tissues. Colitis was associated with decreased food intake and body weight, augmented spleen weight, and increased levels of colonic TNF-α, IL-6, and MDA. APP or EHNA, but not dexamethasone, improved food intake and body weight. APP, EHNA, and dexamethasone counteracted the increments of spleen weight, ameliorated macroscopic and microscopic indexes of inflammation, and reduced TNF-α, IL-6, and MDA levels. The beneficial effects of APP and EHNA on inflammatory parameters were prevented by the pharmacological blockade of A(2A) or A(3) receptors, but not A(1) or A(2B). The present results show that: 1) bowel inflammation is associated with an enhanced adenosine deaminase expression; and 2) the anti-inflammatory actions of adenosine deaminase inhibitors against chronic established colitis depend on the sparing of endogenous adenosine, leading to enhanced A(2A) and A(3) receptor activation.</description><subject>Adenine - analogs &amp; derivatives</subject><subject>Adenine - pharmacology</subject><subject>Adenine - therapeutic use</subject><subject>Adenosine Deaminase - biosynthesis</subject><subject>Adenosine Deaminase Inhibitors</subject><subject>Animals</subject><subject>Blotting, Western</subject><subject>Body Weight - drug effects</subject><subject>Chronic Disease</subject><subject>Colitis - enzymology</subject><subject>Colitis - immunology</subject><subject>Colitis - metabolism</subject><subject>Colitis - prevention &amp; control</subject><subject>Colon - drug effects</subject><subject>Colon - enzymology</subject><subject>Colon - immunology</subject><subject>Colon - metabolism</subject><subject>Cytokines - immunology</subject><subject>Disease Models, Animal</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Male</subject><subject>Organ Size - drug effects</subject><subject>Pyrazoles - pharmacology</subject><subject>Pyrazoles - therapeutic use</subject><subject>Pyrimidines - pharmacology</subject><subject>Pyrimidines - therapeutic use</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Receptor, Adenosine A2A - metabolism</subject><subject>Receptor, Adenosine A3 - metabolism</subject><issn>1521-0103</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkDtPwzAUhS0kREthZkPemAK247zGqIKCVImle3TjXFOXJA62I8Ef4HfjijIwnfv4dKRzCLnh7J5zIR8OE4Y4xa3gQqRnZMkzwRPGWbogl94fGONS5ukFWQiW5yXL0iX53u2Rtr1V79AhtZpGGa03I9IOYTAjeKQwYG-sg4Ceqr2zo1EUPyd0ZsAxQE-V7U0wnob4nN_2UZE6VG424Uj8961FTWHsaJ0eGZyCdf6KnGvoPV6fdEV2T4-79XOyfd28rOttMnGRhQR03nLImeZdqaQoq5YrkYmiZEJLVXKOCoRADZnWvFBKgtDxWnalRMa6dEXufm0nZz9m9KEZjFfY9zCinX1TZFWsrKpkJG9P5NwO2DVTzAruq_lrLv0BoQxxQA</recordid><startdate>201011</startdate><enddate>201011</enddate><creator>Antonioli, Luca</creator><creator>Fornai, Matteo</creator><creator>Colucci, Rocchina</creator><creator>Awwad, Oriana</creator><creator>Ghisu, Narcisa</creator><creator>Tuccori, Marco</creator><creator>Da Settimo, Federico</creator><creator>La Motta, Concettina</creator><creator>Natale, Gianfranco</creator><creator>Duranti, Emiliano</creator><creator>Virdis, Agostino</creator><creator>Blandizzi, Corrado</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201011</creationdate><title>The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors</title><author>Antonioli, Luca ; Fornai, Matteo ; Colucci, Rocchina ; Awwad, Oriana ; Ghisu, Narcisa ; Tuccori, Marco ; Da Settimo, Federico ; La Motta, Concettina ; Natale, Gianfranco ; Duranti, Emiliano ; Virdis, Agostino ; Blandizzi, Corrado</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p125t-af6b1a60f1d8c4289b1c2527802f4c811eca22efa5ff17cc4a2f8118d84e00d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adenine - analogs &amp; derivatives</topic><topic>Adenine - pharmacology</topic><topic>Adenine - therapeutic use</topic><topic>Adenosine Deaminase - biosynthesis</topic><topic>Adenosine Deaminase Inhibitors</topic><topic>Animals</topic><topic>Blotting, Western</topic><topic>Body Weight - drug effects</topic><topic>Chronic Disease</topic><topic>Colitis - enzymology</topic><topic>Colitis - immunology</topic><topic>Colitis - metabolism</topic><topic>Colitis - prevention &amp; control</topic><topic>Colon - drug effects</topic><topic>Colon - enzymology</topic><topic>Colon - immunology</topic><topic>Colon - metabolism</topic><topic>Cytokines - immunology</topic><topic>Disease Models, Animal</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Male</topic><topic>Organ Size - drug effects</topic><topic>Pyrazoles - pharmacology</topic><topic>Pyrazoles - therapeutic use</topic><topic>Pyrimidines - pharmacology</topic><topic>Pyrimidines - therapeutic use</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Receptor, Adenosine A2A - metabolism</topic><topic>Receptor, Adenosine A3 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Antonioli, Luca</creatorcontrib><creatorcontrib>Fornai, Matteo</creatorcontrib><creatorcontrib>Colucci, Rocchina</creatorcontrib><creatorcontrib>Awwad, Oriana</creatorcontrib><creatorcontrib>Ghisu, Narcisa</creatorcontrib><creatorcontrib>Tuccori, Marco</creatorcontrib><creatorcontrib>Da Settimo, Federico</creatorcontrib><creatorcontrib>La Motta, Concettina</creatorcontrib><creatorcontrib>Natale, Gianfranco</creatorcontrib><creatorcontrib>Duranti, Emiliano</creatorcontrib><creatorcontrib>Virdis, Agostino</creatorcontrib><creatorcontrib>Blandizzi, Corrado</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Antonioli, Luca</au><au>Fornai, Matteo</au><au>Colucci, Rocchina</au><au>Awwad, Oriana</au><au>Ghisu, Narcisa</au><au>Tuccori, Marco</au><au>Da Settimo, Federico</au><au>La Motta, Concettina</au><au>Natale, Gianfranco</au><au>Duranti, Emiliano</au><au>Virdis, Agostino</au><au>Blandizzi, Corrado</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors</atitle><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle><addtitle>J Pharmacol Exp Ther</addtitle><date>2010-11</date><risdate>2010</risdate><volume>335</volume><issue>2</issue><spage>434</spage><epage>442</epage><pages>434-442</pages><eissn>1521-0103</eissn><abstract>Adenosine modulates immune/inflammatory reactions. This study investigates the expression of adenosine deaminase in the inflamed colon, the effects of adenosine deaminase inhibitors on established colitis, and the recruitment of adenosine receptors by endogenous adenosine after adenosine deaminase blockade. Adenosine deaminase expression was determined by Western blot. The effects of 4-amino-2-(2-hydroxy-1-decyl)pyrazole[3,4-d]pyrimidine (APP; a novel adenosine deaminase inhibitor), erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA; a reference adenosine deaminase inhibitor), dexamethasone, and selective adenosine receptor antagonists were tested in rats with 2,4-dinitrobenzenesulfonic acid-induced colitis. Systemic (food intake, body and spleen weight) and colonic [macroscopic/microscopic damage, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and malondialdehyde (MDA)] inflammatory parameters were assessed. Test drugs were administered intraperitoneally for 6 days, starting at day 5 from colitis induction. Adenosine deaminase was detected in normal colon, and its expression was increased in inflamed tissues. Colitis was associated with decreased food intake and body weight, augmented spleen weight, and increased levels of colonic TNF-α, IL-6, and MDA. APP or EHNA, but not dexamethasone, improved food intake and body weight. APP, EHNA, and dexamethasone counteracted the increments of spleen weight, ameliorated macroscopic and microscopic indexes of inflammation, and reduced TNF-α, IL-6, and MDA levels. The beneficial effects of APP and EHNA on inflammatory parameters were prevented by the pharmacological blockade of A(2A) or A(3) receptors, but not A(1) or A(2B). The present results show that: 1) bowel inflammation is associated with an enhanced adenosine deaminase expression; and 2) the anti-inflammatory actions of adenosine deaminase inhibitors against chronic established colitis depend on the sparing of endogenous adenosine, leading to enhanced A(2A) and A(3) receptor activation.</abstract><cop>United States</cop><pmid>20668053</pmid><doi>10.1124/jpet.110.171223</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier EISSN: 1521-0103
ispartof The Journal of pharmacology and experimental therapeutics, 2010-11, Vol.335 (2), p.434-442
issn 1521-0103
language eng
recordid cdi_proquest_miscellaneous_759521994
source MEDLINE; Alma/SFX Local Collection
subjects Adenine - analogs & derivatives
Adenine - pharmacology
Adenine - therapeutic use
Adenosine Deaminase - biosynthesis
Adenosine Deaminase Inhibitors
Animals
Blotting, Western
Body Weight - drug effects
Chronic Disease
Colitis - enzymology
Colitis - immunology
Colitis - metabolism
Colitis - prevention & control
Colon - drug effects
Colon - enzymology
Colon - immunology
Colon - metabolism
Cytokines - immunology
Disease Models, Animal
Enzyme Inhibitors - pharmacology
Enzyme Inhibitors - therapeutic use
Male
Organ Size - drug effects
Pyrazoles - pharmacology
Pyrazoles - therapeutic use
Pyrimidines - pharmacology
Pyrimidines - therapeutic use
Rats
Rats, Sprague-Dawley
Receptor, Adenosine A2A - metabolism
Receptor, Adenosine A3 - metabolism
title The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T22%3A05%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20blockade%20of%20adenosine%20deaminase%20ameliorates%20chronic%20experimental%20colitis%20through%20the%20recruitment%20of%20adenosine%20A2A%20and%20A3%20receptors&rft.jtitle=The%20Journal%20of%20pharmacology%20and%20experimental%20therapeutics&rft.au=Antonioli,%20Luca&rft.date=2010-11&rft.volume=335&rft.issue=2&rft.spage=434&rft.epage=442&rft.pages=434-442&rft.eissn=1521-0103&rft_id=info:doi/10.1124/jpet.110.171223&rft_dat=%3Cproquest_pubme%3E759521994%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=759521994&rft_id=info:pmid/20668053&rfr_iscdi=true